Skip to main content

Advertisement

Table 1 Patient characteristics

From: Sequencing and curation strategies for identifying candidate glioblastoma treatments

  n = 30
Age, median (range) 63 (25–81)
Female, no. (%) 12 (40%)
Resections, no. (%)
 Initial 19 (63%)
 Biopsy only 2 (7%)
 Re-resection 7 (23%)
 Re-resection of subtotal 2 (7%)
Prior treatment of 7 recurrent tumors, no.
 RT/TMZ 6
 Bevacizumab 3
 Cetuximab 2
 RT/Nivolimab 1
 RT/Rindopepimut 1
 CCNU 1
 Gamma knife 1
 Prior cranial RT, unrelated to GBM 1
Days from initial resection to sample submission, median (IQR) 67 (266)
Sample preservation, no. (%) n = 33
 Fresh frozen 13 (40%)
 OCT embedded 12 (36%)
 Formalin-fixed paraffin-embedded 8 (24%)
Tumor biomarkers, no./no. assessed
 EGFR amplification 8/20
 MGMT methylation 12/30
 IDH1 R132H mutation 2/30
  1. All tumors were histologically confirmed as WHO grade IV gliomas. However, one had focal sarcomatous features, another was initially reviewed as pleomorphic xanthoastrocytoma with anaplastic features then as an epitheliod GBM upon re-revew, and a third had a PNET-like component. SD = standard deviation, IQR = interquartile range, RT = radiation therapy, TMZ = temozolomide, CCNU = Lomustine